Dexcom Inc

DXCM is in a Stage 2 corrective phase within an overall uptrend, pulling back into the rising 50-period SMA. Medium-term bias remains bullish as long as the 50 SMA holds. Short-term price is below the 9- and 20-period EMAs, signaling a pause rather than a reversal. Execution should be deferred until a clear bounce or reversal candle off the 50 SMA confirms support. A breakdown below this zone risks a deeper retracement toward the 200-period SMA.

• ↑Q2 2026 revenue $1.31 B (+13% YoY) driven by global CGM demand
• ↑Anticipated Medicare coverage for ~12 M type 2 patients expands addressable market
• ↓Negative earnings yield suggests stock may be overvalued amid competitive pressure